This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: September 30th, 2009 - September 30th, 2010
This activity is no longer available for credit, however its content is still relevant for your educational needs.
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).
Target Audience
This activity was developed for pharmacists involved in the treatment and management of patients with MM.
Learning Objectives
At the completion of this activity participants should be able to:
- Identify new therapeutic options for the treatment of patients with MM
- Describe strategies for the retreatment of relapsed MM patients
- Discuss role(s) the oncology pharmacist has in the overall management of the MM patient
Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|
Name of Planner or Manager |
Company |
Reported Financial Relationship |
| Nancy Nesser, PharmD, JD | MLI | Nothing to disclose |
| Elizabeth Cohen | COEXM | Nothing to disclose |
Faculty Disclosures
*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.
Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.
Stephanie Taber, PharmD, BCOP has nothing to disclose.
James O. Armitage, MD is a consultant for Allos, Eisai, Seattle Genetics, and Ziopharm.
*Jonathan Kaufman, MD, is a consultant for Celgene and Millennium.
Beth Faiman, RN, MSN, APRN, BC, AOCN is on the speaker's bureau for Millennium and Celgene.
*Content will include non-FDA-approved uses.
Disclaimer
The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.
